Steven “Steve” Chapman is the CEO of Natera, a global leader in cell-free DNA testing with a focus on women's health, oncology, and organ health. Chapman has been in the role of CEO since 2019, and he also sits on the board of directors.
Chapman has been with Natera since 2010, previously serving as chief operating officer, chief commercial officer, senior vice president for commercial operations and vice president of sales. As COO, he led Natera’s commercial entry to the competitive non-invasive prenatal testing market, in which itsPanorama® test reached market leader-status despite being fourth to market.
In his role as CEO, Chapman has played an instrumental role in expanding Natera’s core technology to address new oncology and organ health markets, securing swift commercial growth for the Prospera™ transplant assessment test and establishing the company’s leadership in molecular residual disease testing via Signatera.™ During his tenure, the company has seen year-over-year growth in revenue of more than 40 percent, consistently outperforming earnings expectations.
Before joining Natera, he worked with Genzyme Genetics, a biotechnology company. While there, Chapman delivered record-breaking commercial growth and led strategies that altered pregnancy genetic testing. He started his career as a researcher in the human genetics department at the University of California, Los Angeles, where he earned his B.S. in microbiology, immunology and molecular genetics.
What is Steven Leonard Chapman's net worth?
The estimated net worth of Steven Leonard Chapman is at least $23.62 million as of August 15th, 2024. Mr. Chapman owns 200,710 shares of Natera stock worth more than $23,615,539 as of September 9th. This net worth estimate does not reflect any other investments that Mr. Chapman may own. Additionally, Mr. Chapman receives a salary of $1,150,000.00 as CEO at Natera. Learn More about Steven Leonard Chapman's net worth.
How old is Steven Leonard Chapman?
What is Steven Leonard Chapman's salary?
How do I contact Steven Leonard Chapman?
Has Steven Leonard Chapman been buying or selling shares of Natera?
During the past quarter, Steven Leonard Chapman has sold $6,028,432.65 in shares of Natera stock. Most recently, Steven Leonard Chapman sold 5,583 shares of the business's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $118.91, for a transaction totalling $663,874.53. Following the completion of the sale, the chief executive officer now directly owns 200,710 shares of the company's stock, valued at $23,866,426.10. Learn More on Steven Leonard Chapman's trading history.
Who are Natera's active insiders?
Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), John Fesko (Insider), James Healy (Director), Gail Marcus (Director), Solomon Moshkevich (President, Clinical Diagnostics), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.
Are insiders buying or selling shares of Natera?
During the last twelve months, insiders at the medical research company sold shares 73 times. They sold a total of 1,288,283 shares worth more than $92,687,204.80. The most recent insider tranaction occured on August, 15th when insider Jonathan Sheena sold 12,000 shares worth more than $1,452,120.00. Insiders at Natera own 7.6% of the company.
Learn More about insider trades at Natera. Information on this page was last updated on 8/15/2024.